BNB Stabilizes Near $780 After Windtree Therapeutics Announces $520M Treasury Allocation
BNB rebounded sharply after pharmaceutical firm Windtree Therapeutics revealed a $520 million commitment to the token for its corporate treasury — a significant non-crypto institutional move into a non-bitcoin asset.
The token gained 0.6% over the past 24 hours, recovering from a dip to $761.22 and briefly touching $785.75. According to CoinDesk Research, the recovery followed a sharp selloff where volume surged to more than double the daily average, pushing prices down from $774.52 to $761.34 before a swift reversal.
BNB’s V-shaped recovery was fueled by Windtree’s strategic entry, bolstering confidence among market participants. The $520 million allocation ranks among the largest BNB purchases by a traditional company to date, following in the footsteps of firms like Nano Labs that are betting on the token’s long-term trajectory.
BNB’s supply continues to decline through ongoing token burns by Binance and BNB Chain, enhancing its scarcity narrative. Meanwhile, the BNB Chain ecosystem is expanding with the latest cohort of its Most Valuable Builder accelerator, supporting 15 startups across AI, DeFi, and real-world asset tokenization.
BNB now trades just below $780, with technical models indicating signs of consolidation around this level. Analysts say sustained institutional demand and ecosystem development will be key drivers for further upside.
